Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL VIROLOGY TESTING MARKET MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL VIROLOGY TESTING MARKET MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL VIROLOGY TESTING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMEWORK
8 GLOBAL VIROLOGY TESTING MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 RT-PCR TESTS
8.2.1 MARKET VALUE (USD MN)
8.2.2 MARKET VOLUME (UNITS)
8.2.3 AVERAGE SELLING PRICE (USD)
8.3 ISOTHERMAL NUCLEIC ACID AMPLICFICATION TEST
8.3.1 MARKET VALUE (USD MN)
8.3.2 MARKET VOLUME (UNITS)
8.3.3 AVERAGE SELLING PRICE (USD)
8.4 ANTIGEN TEST KITS
8.4.1 LATEX AGGLUTINATION TESTS
8.4.1.1. MARKET VALUE (USD MN)
8.4.1.2. MARKET VOLUME (UNITS)
8.4.1.3. AVERAGE SELLING PRICE (USD)
8.4.2 IMMUNOCHROMATOGRAPHIC (LATERAL FLOW ASSAY)
8.4.2.1. MARKET VALUE (USD MN)
8.4.2.2. MARKET VOLUME (UNITS)
8.4.2.3. AVERAGE SELLING PRICE (USD)
8.4.3 RAPID RESPIRATORY INFECTION TEST
8.4.3.1. MARKET VALUE (USD MN)
8.4.3.2. MARKET VOLUME (UNITS)
8.4.3.3. AVERAGE SELLING PRICE (USD)
8.4.4 FLORESCENCE IMMUNOASSAY TEST
8.4.4.1. MARKET VALUE (USD MN)
8.4.4.2. MARKET VOLUME (UNITS)
8.4.4.3. AVERAGE SELLING PRICE (USD)
8.4.5 COLORIMETRY TEST
8.4.5.1. MARKET VALUE (USD MN)
8.4.5.2. MARKET VOLUME (UNITS)
8.4.5.3. AVERAGE SELLING PRICE (USD)
8.4.6 OTHERS
8.5 ANTIBODY TEST KITS
8.5.1 RAPID DIAGNOSTIC TEST
8.5.1.1. MARKET VALUE (USD MN)
8.5.1.2. MARKET VOLUME (UNITS)
8.5.1.3. AVERAGE SELLING PRICE (USD)
8.5.2 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
8.5.2.1. MARKET VALUE (USD MN)
8.5.2.2. MARKET VOLUME (UNITS)
8.5.2.3. AVERAGE SELLING PRICE (USD)
8.5.3 NEUTRALIZATION ASSAY KITS
8.5.3.1. MARKET VALUE (USD MN)
8.5.3.2. MARKET VOLUME (UNITS)
8.5.3.3. AVERAGE SELLING PRICE (USD)
8.5.4 AGAR GEL IMMUNODIFFUTION ASSAY
8.5.4.1. MARKET VALUE (USD MN)
8.5.4.2. MARKET VOLUME (UNITS)
8.5.4.3. AVERAGE SELLING PRICE (USD)
8.5.5 CHEMILUMINESCENT IMMUNOASSAY
8.5.6 OTHERS
9 GLOBAL VIROLOGY TESTING MARKET, BY DIAGNOSTIC TECHNIQUE
9.1 OVERVIEW
9.2 MOLECULAR DIAGNOSTICS
9.2.1 NGS
9.2.2 PCR
9.2.3 RT-PCR
9.2.4 QPCR
9.2.5 OTHERS
9.3 MICROARRAY TEST
9.4 IMMUNOASSAYS
9.4.1 ELISA
9.4.2 FLUOROIMMUNOASSAYS
9.4.3 CHEMILUMINIESCENT IMMUNOASSAY
9.4.4 LATERAL FLOW ASSAY
9.4.5 OTHERS
9.5 MASS SPECTROSCOPY
9.5.1 CHARGE-DETECTION MASS SPECTROMETRY (CDMS)
9.5.2 ION MOBILITY MASS SPECTROMETRY (IMS)
9.5.3 OTHERS
9.6 FLUROSCENT DETECTION TECHIQUES
9.6.1 FLOW CYTOMETRY
9.6.2 OTHERS
9.7 NEGATIVE STAING ELECTRO MICROSCOPY TEST
9.8 OTHERS
10 GLOBAL VIROLOGY TESTING MARKET, BY TESTING TYPE
10.1 OVERVIEW
10.2 PRELIMINARY SCREENING TESTS
10.3 CONFIRMATORY TESTS
11 GLOBAL VIROLOGY TESTING MARKET, BY VIRUS TYPE
11.1 OVERVIEW
11.2 INFLUENZA
11.2.1 INFLUENZA A
11.2.2 INFLUENZA B
11.2.3 INFLUENZA C
11.3 HEPATITIS
11.3.1 HEPATITIS A
11.3.2 HEPATITIS B
11.3.3 HEPATITIS C
11.3.4 HEPATITIS D
11.3.5 HEPATITIS E
11.4 HPV
11.5 HIV
11.6 MEASLES
11.7 RUBELLA
11.8 CORONA VIRUS
11.9 DENGUE
11.1 HERPES
11.10.1 HERPES SIMPLEX
11.10.2 HERPES ZOSTER
11.11 CHIKUNGUNYA VIRUS
11.12 ZIKA
11.13 EBOLA
11.14 OTHERS
12 GLOBAL VIROLOGY TESTING MARKET, BY SAMPLE TYPE
12.1 OVERVIEW
12.2 BLOOD
12.3 SALIVA
12.4 URINE
12.5 STOOL (FECES)
12.6 SPINAL FLUID
12.7 SPUTUM
12.8 ORGAN TISSUE
12.9 OTHERS
13 GLOBAL VIROLOGY TESTING MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 SKIN AND SOFT TISSUE INFECTIONS
13.3 RESPIRATORY TRACT INFECTIONS
13.4 GI TRACT INFECTIONS
13.5 URINARY TRACT INFECTION
13.6 EYE INFECTIONS
13.7 SEXUALLY TRANSMITTED DISEASES
13.8 PERINATAL INFECTIONS
13.9 OTHERS
14 GLOBAL VIROLOGY TESTING MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL ASSISTED LABORATORY
14.3 DIAGNOSTIC CENTERS/LABORATORY
14.4 PHARMA AND BIOTECH COMPANIES
14.5 BLOOD BANKS
14.6 CLINICS
14.7 ACADEMIC/RESEARCH INSTITUTES
14.8 PHARMACIES
14.9 OTHERS
15 GLOBAL VIROLOGY TESTING MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 GLOBAL VIROLOGY TESTING MARKET, BY REGION
16.1 GLOBAL VIROLOGY TESTING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1.1 NORTH AMERICA
16.1.1.1. U.S.
16.1.1.2. CANADA
16.1.1.3. MEXICO
16.1.2 EUROPE
16.1.2.1. GERMANY
16.1.2.2. FRANCE
16.1.2.3. U.K.
16.1.2.4. HUNGARY
16.1.2.5. LITHUANIA
16.1.2.6. AUSTRIA
16.1.2.7. IRELAND
16.1.2.8. NORWAY
16.1.2.9. POLAND
16.1.2.10. ITALY
16.1.2.11. SPAIN
16.1.2.12. RUSSIA
16.1.2.13. TURKEY
16.1.2.14. BELGIUM
16.1.2.15. NETHERLANDS
16.1.2.16. SWITZERLAND
16.1.2.17. REST OF EUROPE
16.1.3 ASIA-PACIFIC
16.1.3.1. JAPAN
16.1.3.2. CHINA
16.1.3.3. SOUTH KOREA
16.1.3.4. INDIA
16.1.3.5. AUSTRALIA
16.1.3.6. SINGAPORE
16.1.3.7. THAILAND
16.1.3.8. MALAYSIA
16.1.3.9. INDONESIA
16.1.3.10. PHILIPPINES
16.1.3.11. VIETNAM
16.1.3.12. REST OF ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.4.1. BRAZIL
16.1.4.2. ARGENTINA
16.1.4.3. PERU
16.1.4.4. REST OF SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.1.5.1. SOUTH AFRICA
16.1.5.2. SAUDI ARABIA
16.1.5.3. UAE
16.1.5.4. EGYPT
16.1.5.5. KUWAIT
16.1.5.6. ISRAEL
16.1.5.7. REST OF MIDDLE EAST AND AFRICA
16.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL VIROLOGY TESTING MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL VIROLOGY TESTING MARKET, SWOT AND DBR ANALYSIS
19 GLOBAL VIROLOGY TESTING MARKET, COMPANY PROFILE
19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 THERMO FISHER SCIENTIFIC INC.
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 QIAGEN
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 ABBOTT
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 SIEMENS HEALTHCARE GMBH
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 F. HOFFMANN-LA ROCHE LTD
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENTS
19.7 ILLUMINA, INC.
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPMENTS
19.8 DIASORIN S.P.A.
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPMENTS
19.9 BIO-RAD LABORATORIES, INC.,
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPMENTS
19.1 SEQUENOM
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPMENTS
19.11 BIOMÉRIEUX SA
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENTS
19.12 HOLOGIC, INC.
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 LEICA BIOSYSTEMS NUSSLOCH GMBH
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENTS
19.14 EUROFINS SCIENTIFIC
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPMENTS
19.15 SENTINEL
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPMENTS
19.16 DANAHER
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPMENTS
19.17 RESPONSE BIOMEDICAL
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPMENTS
19.18 BD
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPMENTS
19.19 QUIDEL CORPORATION
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPMENTS
19.2 MERIDIAN BIOSCIENCE
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPMENTS
19.21 GENMARK DIAGNOSTICS, INC.
19.21.1 COMPANY OVERVIEW
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHIC PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPMENTS
19.22 SA SCIENTIFIC
19.22.1 COMPANY OVERVIEW
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHIC PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPMENTS
19.23 SEKISUI DIAGNOSTICS
19.23.1 COMPANY OVERVIEW
19.23.2 REVENUE ANALYSIS
19.23.3 GEOGRAPHIC PRESENCE
19.23.4 PRODUCT PORTFOLIO
19.23.5 RECENT DEVELOPMENTS
19.24 GRIFOLS S.A.
19.24.1 COMPANY OVERVIEW
19.24.2 REVENUE ANALYSIS
19.24.3 GEOGRAPHIC PRESENCE
19.24.4 PRODUCT PORTFOLIO
19.24.5 RECENT DEVELOPMENTS
19.25 TECAN TRADING AG
19.25.1 COMPANY OVERVIEW
19.25.2 REVENUE ANALYSIS
19.25.3 GEOGRAPHIC PRESENCE
19.25.4 PRODUCT PORTFOLIO
19.25.5 RECENT DEVELOPMENTS
19.26 ELITECH GROUP
19.26.1 COMPANY OVERVIEW
19.26.2 REVENUE ANALYSIS
19.26.3 GEOGRAPHIC PRESENCE
19.26.4 PRODUCT PORTFOLIO
19.26.5 RECENT DEVELOPMENTS
19.27 ALTONA DIAGNOSTICS GMBH
19.27.1 COMPANY OVERVIEW
19.27.2 REVENUE ANALYSIS
19.27.3 GEOGRAPHIC PRESENCE
19.27.4 PRODUCT PORTFOLIO
19.27.5 RECENT DEVELOPMENTS
19.28 CORIS BIOCONCEPT
19.28.1 COMPANY OVERVIEW
19.28.2 REVENUE ANALYSIS
19.28.3 GEOGRAPHIC PRESENCE
19.28.4 PRODUCT PORTFOLIO
19.28.5 RECENT DEVELOPMENTS
19.29 TAUNS LABORATORIES
19.29.1 COMPANY OVERVIEW
19.29.2 REVENUE ANALYSIS
19.29.3 GEOGRAPHIC PRESENCE
19.29.4 PRODUCT PORTFOLIO
19.29.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUESTRELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
